NEWS DETAIL

FDA D.I.S.C.O. 速覽：FDA 核准 Augtyro（repotrectinib）用於治療 NTRK 基因融合陽性實體瘤，Krazati（adagrasib）用於治療 KRAS G12C 突變型結直腸癌

Listen to a soundcast of the June 13, 2024, and June 21, 2024, Augtyro (repotrectinib) for NTRK…

醫藥資訊 July 4, 2026

该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

文章相關商品

系統已根據文章標題、摘要和正文，自動匹配目前在售的強相關藥品。

常見問題

Which products are related to this article?

The system matched these relevant products from the article content: 阿達格拉西布片 ADADX Adagrasib、盧修斯阿達格拉西布 Adagrasib 在線購買、瑞普替尼膠囊 REPODX Repotrectinib、盧修斯瑞普替尼 Repotrectinib 線上購買.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

FDA D.I.S.C.O. 速覽：FDA 核准 Augtyro（repotrectinib）用於治療 NTRK 基因融合陽性實體瘤，Krazati（adagrasib）用於治療 KRAS G12C 突變型結直腸癌

文章相關商品

阿達格拉西布片 ADADX Adagrasib

盧修斯 阿達格拉西布 Adagrasib 在線購買

瑞普替尼膠囊 REPODX Repotrectinib

盧修斯 瑞普替尼 Repotrectinib 線上購買

常見問題

盧修斯阿達格拉西布 Adagrasib 在線購買

盧修斯瑞普替尼 Repotrectinib 線上購買